JP2013511559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511559A5 JP2013511559A5 JP2012540228A JP2012540228A JP2013511559A5 JP 2013511559 A5 JP2013511559 A5 JP 2013511559A5 JP 2012540228 A JP2012540228 A JP 2012540228A JP 2012540228 A JP2012540228 A JP 2012540228A JP 2013511559 A5 JP2013511559 A5 JP 2013511559A5
- Authority
- JP
- Japan
- Prior art keywords
- mirna
- cancer
- use according
- mir
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 8
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 8
- 108091070501 miRNA Proteins 0.000 claims 8
- 239000002679 microRNA Substances 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 108091023818 miR-7 stem-loop Proteins 0.000 claims 5
- 239000002243 precursor Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009905758 | 2009-11-24 | ||
| AU2009905758A AU2009905758A0 (en) | 2009-11-24 | Method of Modulating Epidermal Growth Factor (EGF) Ligands | |
| PCT/AU2010/001577 WO2011063455A1 (en) | 2009-11-24 | 2010-11-24 | Modulation of epidermal growth factor receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511559A JP2013511559A (ja) | 2013-04-04 |
| JP2013511559A5 true JP2013511559A5 (enExample) | 2014-01-16 |
Family
ID=44065735
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540228A Pending JP2013511559A (ja) | 2009-11-24 | 2010-11-24 | 上皮成長因子受容体リガンドのモジュレーション |
| JP2012540229A Pending JP2013511560A (ja) | 2009-11-24 | 2010-11-24 | チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540229A Pending JP2013511560A (ja) | 2009-11-24 | 2010-11-24 | チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9051551B2 (enExample) |
| EP (2) | EP2504014A4 (enExample) |
| JP (2) | JP2013511559A (enExample) |
| CN (2) | CN102762213A (enExample) |
| AU (2) | AU2010324529A1 (enExample) |
| CA (2) | CA2781572A1 (enExample) |
| DK (1) | DK2521555T3 (enExample) |
| ES (1) | ES2608923T3 (enExample) |
| WO (2) | WO2011063456A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| EP2591106A1 (en) * | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| BR112014012495A2 (pt) * | 2011-11-25 | 2017-06-06 | Assist Publique - Hopitaux De Paris | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer |
| FR2984168B1 (fr) * | 2011-12-19 | 2019-07-05 | Chanel Parfums Beaute | Micro-rna pour leur utilisation dans la pigmentation |
| US20150126621A1 (en) * | 2012-05-15 | 2015-05-07 | New York University | METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS |
| IN2015DN04209A (enExample) * | 2012-10-18 | 2015-10-16 | Univ Western Australia | |
| WO2014143855A2 (en) * | 2013-03-15 | 2014-09-18 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
| US20140308274A1 (en) * | 2013-03-15 | 2014-10-16 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors |
| CA2919477A1 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| CN108537001B (zh) * | 2018-04-12 | 2021-06-01 | 华中科技大学鄂州工业技术研究院 | 一种预测用于治疗肝癌的特异性治疗药物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1797183T3 (da) * | 2004-09-02 | 2012-10-01 | Univ Yale | Regulering af onkogener med mikrornas |
| ES2534300T3 (es) * | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| ES2534430T3 (es) | 2006-08-28 | 2015-04-22 | The University Of Western Australia | Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN |
| EP2104737B1 (en) | 2006-12-08 | 2013-04-10 | Asuragen, INC. | Functions and targets of let-7 micro rnas |
| US20100173954A1 (en) | 2007-01-19 | 2010-07-08 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
-
2010
- 2010-11-24 US US13/511,181 patent/US9051551B2/en active Active
- 2010-11-24 AU AU2010324529A patent/AU2010324529A1/en not_active Abandoned
- 2010-11-24 CN CN2010800604001A patent/CN102762213A/zh active Pending
- 2010-11-24 AU AU2010324530A patent/AU2010324530B2/en not_active Ceased
- 2010-11-24 JP JP2012540228A patent/JP2013511559A/ja active Pending
- 2010-11-24 ES ES10832418.7T patent/ES2608923T3/es active Active
- 2010-11-24 CA CA2781572A patent/CA2781572A1/en not_active Abandoned
- 2010-11-24 DK DK10832418.7T patent/DK2521555T3/en active
- 2010-11-24 EP EP10832417.9A patent/EP2504014A4/en not_active Withdrawn
- 2010-11-24 CA CA2781571A patent/CA2781571A1/en not_active Abandoned
- 2010-11-24 JP JP2012540229A patent/JP2013511560A/ja active Pending
- 2010-11-24 CN CN2010800604035A patent/CN102762214A/zh active Pending
- 2010-11-24 EP EP10832418.7A patent/EP2521555B1/en active Active
- 2010-11-24 WO PCT/AU2010/001578 patent/WO2011063456A1/en not_active Ceased
- 2010-11-24 US US13/511,183 patent/US20130090366A1/en not_active Abandoned
- 2010-11-24 WO PCT/AU2010/001577 patent/WO2011063455A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Targeting neuropilin-1 interactions is a promising anti-tumor strategy | |
| Fane et al. | NFIB mediates BRN2 driven melanoma cell migration and invasion through regulation of EZH2 and MITF | |
| De Luca et al. | The role of the EGFR signaling in tumor microenvironment | |
| Nichol et al. | EGFL7: a unique angiogenic signaling factor in vascular development and disease | |
| Van Roy | Beyond E-cadherin: roles of other cadherin superfamily members in cancer | |
| Chiechi et al. | Role of TGF-β in breast cancer bone metastases | |
| Lee et al. | The epithelial–mesenchymal transition: new insights in signaling, development, and disease | |
| Cassell et al. | Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma | |
| Guo et al. | Role of Notch and its oncogenic signaling crosstalk in breast cancer | |
| Clark et al. | A prototypic matricellular protein in the tumor microenvironment—where there's SPARC, there's fire | |
| Wang et al. | Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells | |
| JP2015505843A5 (enExample) | ||
| Mukaida et al. | Fibroblasts, an inconspicuous but essential player in colon cancer development and progression | |
| JP2012017341A5 (enExample) | ||
| Boccaccio et al. | MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure | |
| MX368790B (es) | Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada. | |
| Grisendi et al. | Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers | |
| Zhou et al. | Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche | |
| Belyea et al. | Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting | |
| EA201170155A1 (ru) | Специфические антагонисты рецептора fgf-r4 | |
| NZ588587A (en) | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma | |
| NZ599707A (en) | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ) | |
| JP2013511560A5 (enExample) | ||
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| Yuan et al. | Anti-angiogenic efficacy of 5′-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs |